PAST
Some digestive cancer patients may achieve pathologic complete response (pCR) after neoadjuvant therapy (NAT). 1 According to literature review, a retrospective cohort study 2 showed that pCR was associated with improved overall survival (OS), whereas another study 3 argued that OS did not differ significantly between pCR and non-pCR patients. Therefore, to date, the prognostic impact of pCR on survival in digestive cancers has not been completely established.
PRESENT
First, this study 4 demonstrated that digestive cancer patients who achieved pCR after receiving NAT were more likely to have significantly better OS or disease-free survival (DFS). Second, molecular biology research on the group of patients with pCR should facilitate the finding of sensitive therapeutic targets in order to deliver tailored NAT to individual patients. Finally, pCR can be considered a valuable prognostic factor for better guidance in clinical decision making for postoperative adjuvant treatment and follow-up observation.
FUTURE
Considering the great clinical implications of pCR, the authors plan to explore possibilities for improving the pCR rate in the future, such as adding targeted agents in NAT 5 and using concomitant boost radiotherapy as well as appropriate delay in the interval between NAT and surgery. 6 It is anticipated that the clinical outcomes for digestive cancer patients will be further improved with continuous research progress in increasing the pCR rate.
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